APP and amyloidosis: Blocking ACAT1/SOAT1 activity by genetic ablation or pharmacological inhibition has been shown to reduce amyloid pathology in mice by lowering levels of the amyloid precursor protein (APP) and its toxic product, Aβ [56,57,59].